{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-054508","form_type":"8-K","ticker":"DMRA","cik":"0001800315","company_name":"Damora Therapeutics, Inc.","filed_at":"2023-10-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.508956+00:00","generated_at":"2026-06-09T17:05:33.832095+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Galecto reports 60% response rate in GALLANT-1 part A; halts Part B to focus on liver disease","bullets":["Three of five NSCLC patients at 100 mg GB1211 BID plus atezolizumab achieved partial response vs. 22–38% for atezolizumab monotherapy.","Galecto will not initiate Part B of GALLANT-1, reallocating resources to severe liver diseases as part of strategic alternative process.","Two severe dose-limiting skin reactions occurred at 200 mg dose; no such reactions at the recommended 100 mg dose level.","Galecto to supply GB1211 for an investigator-initiated Phase 2 trial at Providence Portland Medical Center expected in early 2024.","Company plans to explore external options for partnering/funding further oncology activities for GB1211."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-054508","json":"https://secwatch.observer/filing/0000950170-23-054508.json","markdown":"https://secwatch.observer/filing/0000950170-23-054508.md","text":"https://secwatch.observer/filing/0000950170-23-054508.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800315/000095017023054508/0000950170-23-054508-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800315/000095017023054508/glto-20231023.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T17:05:33.832095+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}